FDA Accepts Atara's Tab-cel BLA Resubmission, Sets March 2027 Decision Date
ATRA has more than doubled off its 52-week low of $3.92.
Summary
The FDA accepted the resubmitted BLA for tabelecleucel (tab-cel) in EBV+ PTLD, with a PDUFA target action date of March 31, 2027. This is a major regulatory milestone for Atara, which has faced two prior complete response letters and a going concern warning with only $9.9M in cash as of Q2. If approved, Atara receives a $31 million milestone payment from partner Pierre Fabre plus double-digit tiered royalties on sales. The acceptance validates the resubmission package and sets a concrete approval timeline, though FDA could still issue another CRL. Atara's partner Pierre Fabre controls the BLA and launch strategy, limiting Atara's influence but also its commercialization costs.
At the time of this announcement, ATRA was trading at $9.31 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $93.4M. The 52-week trading range was $3.92 to $19.15. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: BusinessWire.